Will associate with school to market the drug cancer medication
Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu
San Antonio, January 30, 2025 – UT San Antonio health Dentistry school The researcher and her pioneering biotechnology company joined the school to obtain a prestigious subsidy of small business technology of $ 400,000 (STTR) from the National Institutes of Health to accelerate the development of a cancer drug oral.
Cara Gonzales, DDS, PHD, deputy professor in the Department of complete dentistry in Ut Health San Antonio and founder of San Antonio, based in San KeraceuticsStudy CIDD99, a first-rate drug targeting a new anti-cancer pathway, promising an effective option to combat the types of aggressive cancer with fewer unwanted side effects.
This collaboration combines the innovative research capacities of UT Health San Antonio, a world class research university It ranks 12th globally for the impact of its discoveriesWith the entrepreneurial ingenuity of keraceutics. Their shared vision is to develop cutting -edge targeted cancer therapies that offer patients a new hope.
“The partnership between UT Health San Antonio and Keraceuticals is a perfect example of the way in which academic and industry collaboration can lead to transformative medical breakthroughs,” said Gonzales. “CIDD99 represents a daring step in targeting aggressive cancers, and this funding will help us unlock its therapeutic potential and improve results for patients around the world.”
A partnership to advance revolutionary research
The STTR is a subsidy that combines small businesses with research institutions to help market research faster. The highly competitive program is led by the Small Business Administration of the United States and funded by partner agencies, such as the National Institute of Dental and Craniofacial Research of NIH.
Thanks to this partnership, UT Health San Antonio will provide a critical research infrastructure, expertise and preclinical support to advance the CIDD99.
The Gonzales project, entitled “1,3-Thioureas as a first-class mitochondrial inhibitors to treat oral cancer”, is focused on a compound protected by patents which targets a previously unexploited critical path for cancer survival. The partnership will advance this research in order to provide more efficient and less toxic cancer therapies.
“The UT Health San Antonio dentistry school is proud to associate with Dr. Gonzales and the Keraceuticals to bring revolutionary innovations closer to Cidd99 closer to clinical reality,” said Peter M. Loomer, DDS, PHD, MBA, dean of the School of Dentistry ,. “This partnership reflects our commitment to advance scientific discovery and to improve lives through research and advanced collaboration.”
Cidd99’s promise
The oral epidermoid carcinoma, the sixth most common cancer in the world, has one of the lowest survival rates among all cancers, without targeted therapies available for its advanced or recurrent forms. Even with additional treatment, the survival rate for this recurring form is only 6 to 7 months.
The results of patients for oral epidermoid carcinoma have not changed in 50 years, in part because no effective therapy has been developed for its advanced and recurring forms. The partnership between UT Health San Antonio and Keraceuticals is about to meet this unmet urgent need.
The main strengths of CIDD99 development include:
- Target a new path:Attack an unexploited mechanism to considerably reduce the growth and resistance of tumors
- Promising preclinical results:The Keraceuticals lead compound, CIDD99, considerably reducing tumor volumes (5 times) in mouse cancer models
- Large applicability: Powerful anti-cancer effects on several types of cancer, including lung cancers, breast, prostate, brain and non-small cells, many of which have limited treatment options
- Collaboration of innovation:Take advantage of advanced research capacities at Ut Health San Antonio to support the development of drugs and future clinical trials of new therapies against cancer developed by Keraceuticals
These key studies will check the effectiveness of formulations that allow oral and / or IV administration for future clinical trials.
“This collaboration illustrates the dynamic potential of university partnerships to fill the gap between research and patient care,” said Gonzales. “By pooling resources and expertise, Ut Health San Antonio and Keraceuticals accelerate the path of therapies that change their lives for patients fighting against aggressive cancers.”
Center for Health Sciences at the University of Texas in San Antonio (UT Health San Antonio), the main engine in the 44.1 billion dollars health and biosciences in San Antonio dollars, is the largest university research institution in South Texas with an annual research portfolio of more than $ 436 million. Highlighting a substantial economic impact with its six professional schools, a diversified workforce of more than 9,400, an annual expenditure budget of $ 1.67 billion and clinical practices which offer 2.5 million patient visits Each year, UT Health San Antonio provides for continuous growth over the next five years and plans to add more than 1,500 jobs at higher wages to serve San Antonio, the county of Bexar and the South Texas region. To find out more about the many ways “We Making Lives Better®”, visit Uthealthsa.org.
The Ut Health San Antonio Dentistry school Offer 18 degrees and programs in dentistry and dental hygiene, educators of the world’s renowned faculty, a diversified student population, advanced clinical installations and a distinguished research company. Departments include complete dentistry, developmental dentistry, endodontics, periodontics and oral and maxillo-facial surgery. Scientists collaborate with clinicians and world research teams and work in several medical and dental disciplines to find new treatments, advance knowledge on oral health, biomaterials, cancer, pain and more . To find out more, visit https://www.uthscsa.edu/academics/dental.
Stay connected with the University of Texas Health Center in San Antonio on Facebook,, Twitter,, Liendin,, Instagram And YouTube